Thermo Fisher Scientific (NYSE:TMO)‘s stock had its “outperform” rating restated by equities researchers at Leerink Swann in a research report issued on Monday. They presently have a $200.00 target price on the medical research company’s stock, down from their previous target price of $216.00. Leerink Swann’s price objective would suggest a potential upside of 9.62% from the company’s previous close. Leerink Swann also issued estimates for Thermo Fisher Scientific’s Q4 2017 earnings at $2.64 EPS, Q4 2018 earnings at $2.81 EPS, FY2018 earnings at $10.38 EPS and Q1 2019 earnings at $2.62 EPS.
Several other research analysts have also commented on the company. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 target price for the company in a research report on Thursday, September 7th. Morgan Stanley restated an “overweight” rating and set a $220.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday, September 6th. Cowen restated an “outperform” rating and set a $220.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Sunday, September 10th. Deutsche Bank set a $226.00 price objective on Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Thursday, October 26th. Finally, Argus restated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, August 22nd. They noted that the move was a valuation call. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $205.21.
Shares of Thermo Fisher Scientific (NYSE TMO) opened at $182.45 on Monday. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.85. Thermo Fisher Scientific has a twelve month low of $139.88 and a twelve month high of $201.20. The stock has a market capitalization of $77,071.31, a P/E ratio of 21.12, a price-to-earnings-growth ratio of 1.76 and a beta of 1.06.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.24 by $0.07. The company had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. Thermo Fisher Scientific’s revenue for the quarter was up 13.9% compared to the same quarter last year. During the same period in the previous year, the business earned $2.03 EPS. equities analysts anticipate that Thermo Fisher Scientific will post 9.36 earnings per share for the current fiscal year.
In other news, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total value of $9,419,500.00. Following the sale, the chief executive officer now owns 252,577 shares of the company’s stock, valued at approximately $47,582,981.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.49% of the stock is currently owned by insiders.
Institutional investors have recently made changes to their positions in the company. Amalgamated Bank grew its stake in Thermo Fisher Scientific by 57.0% in the second quarter. Amalgamated Bank now owns 44,921 shares of the medical research company’s stock valued at $7,837,000 after purchasing an additional 16,308 shares in the last quarter. Mutual of America Capital Management LLC boosted its stake in shares of Thermo Fisher Scientific by 2.1% during the 2nd quarter. Mutual of America Capital Management LLC now owns 47,728 shares of the medical research company’s stock worth $8,327,000 after acquiring an additional 977 shares in the last quarter. Mitchell Capital Management Co. boosted its stake in shares of Thermo Fisher Scientific by 40.3% during the 2nd quarter. Mitchell Capital Management Co. now owns 44,940 shares of the medical research company’s stock worth $7,841,000 after acquiring an additional 12,910 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its stake in shares of Thermo Fisher Scientific by 0.9% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 580,712 shares of the medical research company’s stock worth $101,317,000 after acquiring an additional 5,213 shares in the last quarter. Finally, San Francisco Sentry Investment Group CA bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth about $1,451,000. 86.16% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This report was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://transcriptdaily.com/2017/12/06/thermo-fisher-scientific-tmo-rating-reiterated-by-leerink-swann.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.